anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aerosol compositions are provided that enhance the therapeutic action of ointments by producing, upon topical application thereof, a sustained cooling effect that provides fast relief form pain and itching as well as a tendency to shrink swollen, inflamed tissue. The compositions contain oils, thickening agents for the oils, and propellant. Aqueous solutions, therapeutic ingredients and various adjuvants may also be present. The specific propellant and the proportion used are selected to provide a deposit with a temperature of about -5° C. to about +5° C. In this temperature range, the deposit is cold enough for the required therapeutic effect, but not so cold as to cause pain or tissue damage. The choice and proportion of thickening agents used are selected to provide a deposit that does not flow or spread. Were the deposit to spread, it would present a large surface area from which propellant present in the deposit would evaporate rapidly. By avoiding spreading, the propellant evaporates more slowly and the cooling effect is more sustained.
OSPHENA is an estrogen agonist/antagonist. OSPHENA is not a hormone. The chemical structure of ospemifene is shown in Figure 1.

The chemical designation is Z-2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]ethanol, and has the empirical formula C24H23ClO2, which corresponds to a molecular weight of 378.9. Ospemifene is a white to off-white crystalline powder that is insoluble in water and soluble in ethanol.

Each OSPHENA tablet contains 60 mg of ospemifene. Inactive ingredients include colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, povidone, pregelatinized starch, sodium starch glycolate, titanium dioxide, and triacetin.
PURPOSE:To provide a fine particle-like flexible preparation used for controlling the release of a medicinal substance such as a medicine, agrochemical, etc. CONSTITUTION:This sustained release preparation is produced by adding a medicinal substance such as a medicine to the mixture of (A) a lactic acid polymer or lactic acid-glycolic acid copolymer having a number-average mol. wt. of 500-5000 with (B) the copolymer of lactic acid or glycolic acid with delta- valerolactone or epsilon-caprolactone having a number-average mol. wt. of 500-5000 in a (A)/(B) weight ratio of 1/1 to 20/1, and subsequently forming the mixture into fine particle-like preparations. The fine particle-like preparation has excellent deformability and flexibility and does not cause occlusion, etc., even when administered into blood capillaries, etc.
An oil-in-water emulsion of a mixture of mono- and tri-glycerides is produced with or without emulsifying agents. Specified emulsifying agents are a fatty acid soap of triethanolamine and an alkali metal (see Group VI). Specification 511,827 is referred to.ALSO:Cosmetics are prepared by incorporating therein an oil-in-water emulsion of one or more triglycerides and one or more monoglycerides with or without emulsifying agents at any convenient stage of manufacture.  The emulsifying agent may be a fatty acid soap of triethauolamine and/or an alkali metal.  In examples the emulsion is prepared by warming sweet almond oil, glyceryl mono-stearate and the propyl ester of p-hydroxy benzoic acid (preservative) to 75 DEG C. filtering, stirring whilst an aqueous solution of triethanolamine is added; the stirrinig continuing until temperature drops to 45 DEG C.  The emulsion is added to kaolin thoroughly mixed with the talc, more kaolin magnesium carbonate (which contains the perfume) and titanium oxide successively added, followed by magnesium stearate and colouring.  Specification 511,827 is referred to.
Key Questions: The purpose of our proposed single-masked multicenter randomized controlled trial is to determine if the Interdisciplinary Team approach to low vision service delivery is more effective than the Basic Low Vision Service in improving visual reading ability for 330 veterans with macular diseases and best corrected visual acuity of 20/50-20/200. Effectiveness will be measured with the Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48), a valid and reliable questionnaire that is administered by telephone to capture changes in patients' self-report of their difficulty reading and performing other daily living activities affected by visual impairment before and after rehabilitation. The primary outcome measure is the comparison of changes in patients' visual reading ability on the VA LV VFQ-48 after they receive low vision care from the Interdisciplinary Team or Basic Low Vision Care program. The secondary outcome measures are comparisons of changes in other VA LV VFQ-48 visual ability scores (overall, mobility, visual information processing, visual motor skills). Hypothesis: The improvement in visual reading ability measured with the VA LV VFQ-48 will be larger for patients who received low vision services from the Interdisciplinary Team than for patients who received the Basic Low Vision Service. Specific Aims:(1) Compare the mean changes in patients' visual reading ability (estimated from patients' difficulty ratings of reading items on the VA LV VFQ-48 before and after low vision service delivery) in the Interdisciplinary Team and Basic Low Vision Care Programs.(2) Compare the mean changes in visual ability \[patients' difficulty ratings of other items on the VA LV VFQ-48 (mobility, visual information processing, visual motor skills) before and after low vision service delivery\] in the Interdisciplinary Team and Basic Low Vision Care programs.(3). Identify the characteristics of patients who benefit from the Interdisciplinary Team and Basic Low Vision Service. (4). Conduct an economic evaluation to compare the costs and cost effectiveness of the Interdisciplinary Team and Basic Low Vision Service.
Participants will receive CNCT19 cell infusion after preconditioning, and they need to be closely monitored for 24 hours following CAR-T cell infusion. Participants are advised to remain in the hospital for a minimum of 14 days following cell infusion. The duration of hospitalization and observation will be determined based on the researcher's comprehensive assessment of the subject's condition.
The first subject will be enrolled in the 1-mcg SP-SAP cohort. A percutaneous intraspinal catheter will be placed at the L5-S1 interspace and the catheter advanced 4-5 cm into the intrathecal space under fluoroscopic guidance. To confirm location, CSF will be aspirated and radioopaque contrast dye injected. 1-mL study drug will be mixed with 1-mL patient CSF fluid and administered intrathecally via the catheter. The catheter will be flushed with 1 mL bolus of saline. Four hours after injection (+15 min), the catheter will be removed and the exit site treated with Neosporin ointment and sterilely dressed. Subjects will be monitored in the recovery room for 4 hours and in the hospital for 24 hours and discharged home. Patients only receive a single IT dose.
The invention belongs to the technical field of pharmaceutical preparations. The invention provides the colistin sulfate soluble powder which has good water solubility, high stability, simple preparation process, good effect of treating bacterial diseases of livestock and poultry and convenient use and the preparation method thereof. The soluble colistin sulfate powder includes colistin sulfate 10-30 weight portions, beta-cyclodextrin 10-30 weight portions, polyglycol 6000 2-5 weight portions and cane sugar 35-78 weight portions. In the soluble colistin sulfate powder provided by the invention, the raw material beta-cyclodextrin is a stabilizer, is slightly soluble in water, does not have hygroscopicity, is easy to form a stable hydrate, and can well solve the problem of agglomeration of colistin sulfate under the conditions of high temperature and high humidity. Polyethylene glycol 6000 is a cosolvent, which can increase the solubility of colistin sulfate in water. The preparation method has the advantages of fewer preparation process flows, simple operation, good stability, lower cost, convenient storage and benefit for large-scale production and market popularization. Convenient administration, and wide application, such as mixed feeding, mixed drinking, and used as additive.
Melanocyte keratinocyte pellet will be prepared. Donor skin will be harvested from the gluteal region ; using a sterile shaving blade mounted on a Kocher's forceps. Cell Suspension will be prepared by placing the donor skin in 0.25% trypsin-EDTA (GIBCO) solution for 40 minutes at 37 ᴼC. sample and trypsin will be poured into a labelled petri dishes then neutralized using ringer's lactate. All the steps will be performed in a laminar air flow bench under strict aseptic conditions. The epidermis will be detached from the dermis which will be discarded. Then the epidermis will be cut into tiny pieces and scrapped so that no pigment is left on the surface. Afterwards, they will be transferred to sterile falcon tubes and centrifuged for 10 minutes at 1,000 rpm. The floating epidermal fragments and supernatant fluid will be removed, leaving the cell pellet containing epidermal cells rich in melanocytes and Keratinocytes at the bottom.
FIELD: veterinary science, molecular biology, generic engineering. SUBSTANCE: invention relates to animals breeding. Invention proposes DNA molecule exhibiting polymorphism by porcine gene alpha-(1,2)-fucosyl- transferase-1. Also, invention proposes method of identification of pigs showing resistance to intestinal diseases associated with E. coli and involving analysis of biological sample taken in pig for the presence of polymorphous gene encoding alpha-(1,2)-fucosyltransferase-1. Invention proposes method for breeding pigs showing resistance to intestinal diseases associated with E. coli and comprising polymorphous gene encoding alpha-(1,2)-fucosyltransferase-1. Also, invention proposes molecular analysis for detection of E. coli F18 receptors in pigs and set for analysis realization. Data concerning the polymorphous gene encoding alpha-(1,2)-fucosyltransferase-1 obtained using the present invention allow to differentiate resistant pigs from susceptible animals, to carry out diagnostic test and to breed pigs exhibiting genetic resistance against diseases associated with E. coli F18. EFFECT: improved method and analysis. 11 cl, 1 dwg, 4 tbl, 11 ex
PROBLEM TO BE SOLVED: To prepare fructose 1,6-diphosphate(FDP) in a dosage form appropriate for injection into a patient in an ischemic or a hypoxic state and a patient undergoing a cardiac bypass operation. SOLUTION: An aqueous solution of FDP or an aqueous solution of the salt is freeze-dried until a solid substance having 10-25% (weight ratio) residual moisture content is produced to thereby produce a partially freeze-dried FDP or a pharmacologically permissible salt thereof. The residual moisture content is especially preferably within the range of 12-16% (weight ratio). The total impurity content can surely be regulated to <=5% (weight ratio) and any single impurity can be regulated to <=1% (weight ratio). The formulation is produced in the interior of a hermetically closed sterile container by filling the FDP in a freeze-drying vial and performing a freeze-drying step. The product stability and storage life are not reduced or restricted with a high moisture content.  The formulation can be preserved at ambient temperature for one or more years without substantially deleting the purity.
Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV background of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca)vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides, a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.
Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
Methods of stimulating muscle regeneration, comprising delivering to a muscle a CCR5 interacting agent or encoding molecule. The CCR5 interacting agent binds to muscle stem cells and stimulates myoblast proliferation and muscle regeneration. One example of the CCR5 interacting agent is NAMPT comprising a cytokine finger motif or a derivative thereof. Methods and compositions include cellular compositions, which expresses the CCR5 interacting agent; including a population of satellite or macrophage cells or their precursors/progeny and their applications in stem cell therapy or for use in treating a muscular deficiency, disorder or injury. The examples show muscle tissue regeneration with minimal fibrosis. Also enabled is a NAMPT polypeptide fragment comprising a C-terminal portion of NAMPT comprising a cytokine finger. Compositions further comprise the NAMPT polypeptide fragment and one or more of; tissue stem cell or macrophage or precursor/progeny, scaffold or a retentive material, tissue delivery enhancing or cell retention moiety.
BACKGROUND: Sideroflexin 1 (SFXN1), a mitochondrial serine transporter implicated in one-carbon metabolism, is a prognostic biomarker in lung adenocarcinoma (LUAD). However, its role in LUAD progression remains elusive. This study aimed to investigate the functional significance of SFXN1 in LUAD and evaluate its potential as a therapeutic target.
METHODS: We analyzed SFXN1 expression and its diagnostic and prognostic value in LUAD using the Pan-cancer TCGA dataset. In vitro assays (CCK-8, cell cycle, EDU, wound-healing, and transwell) were employed to assess the role of SFXN1, complemented by in vivo experiments. RNA sequencing elucidated SFXN1-mediated cellular functions and potential mechanisms. Bulk RNA-seq and scRNA-seq data from TCGA and GEO were used to investigate the correlation between SFXN1 and the tumor immune microenvironment. RT-qPCR, Western blot, and IHC assays validated SFXN1 expression and its impact on the immune microenvironment in LUAD.
RESULTS: SFXN1 was upregulated in LUAD tissues and associated with poor prognosis. RNA-seq and scRNA-seq analyses revealed increased SFXN1 expression in tumor cells, accompanied by decreased infiltration of NK and cytotoxic T cells. SFXN1 knockdown significantly reduced cell proliferation and migration, and the inhibition of ERK phosphorylation and CCL20 expression may be the molecular mechanism involved. In vivo, targeting SFXN1 decreased Tregs infiltration and inhibited tumor growth.
CONCLUSIONS: Our findings suggest that SFXN1 may be a potential therapeutic target for LUAD treatment.
The invention discloses mint medlar milk tea wine and a preparation method thereof. The wine is prepared from the raw materials of, 20-30 part of milk powder, 9-18 parts of black tea, 70-80 parts of corn wine, 20-30 parts of barley malt, 10-20 parts of Chinese arborvilae seed, 5-10 parts of mint, 8-15 parts of medlar, 2-3 parts of sesame stem, 2-3 parts of hyacinth dolichos leaf, 2-3 parts of lotus leaf, 2-3 parts of apple seed, 1-2 parts of roselle calyx, 1-2 parts of tree peony root-bark, 1-2 parts of bottle-gourd seed, 5-10 parts of xylitol, and proper amount of water. With the mint medlar milk tea wine prepared with the formula, nutrients and special functions of natural plants such as medlar and mint are well preserved. The wine also contains nutrients of milk powder. Also, with the added traditional Chinese medicine components, health-care functions are added. The wine provided by the invention has kidney-nourishing, liver-nourishing, eyesight-improving, lung-moistening, detoxifying, heat-clearing, and other functions. With the wine, alcohol harm to human body can be effectively relieved.
The two-component hair treatment product consists of one component (A) and another component (B). Component (A) contains an acid and component (B) contains a base. Less than 3 g of the base and/or acid are soluble in 100 ml of water at 20° C. The acid is preferably a dicarboxylic acid, such as sebacic, dodecanoic dicarboxylic acid or tetradecanoic dicarboxylic acid. The base is preferably ammonia, an alkyl amine or an alkylol amine. Prior to use in a method of permanent hair shaping or hair care, the components are mixed with each other to form a ready-to-apply mixture having an automatically continuously or gradually changing pH that changes within from one to 60 minutes so that damage to the hair due to high pH is avoided. For permanent shaping of hair the initial pH of 8 to 13 falls from about 1 to 4 pH units within from 10 to 30 minutes after mixing the components.
BACKGROUND/AIM: This study aimed to compare dietary intake (DI) after gastrectomy for gastric cancer between patients with (C group) and without (NC group) postoperative surgical complications.
PATIENTS AND METHODS: This prospective observational study enrolled patients who underwent gastrectomy for gastric cancer. DI was assessed using a food frequency questionnaire with 82 food items (FFQW82) during nutritional counseling before surgery and at one and three months after surgery.
RESULTS: A total of 225 patients participated in this study. Of the 225 patients, 193 had no postoperative complications, and 32 had postoperative complications (Clavien-Dindo grade ≥2). The median DI at 1 month postoperatively was 1508 kcal/day in the NC group and 1,470.5 kcal/day in the C group (p=0.175). The median DI at 3 months postoperatively was 1,623 kcal/day in the NC group and 1575 kcal/day in the C group (p=0.473). There was a significant difference between the NC and C groups in the rate of decrease in DI at one month (median: -8.44% vs. -15.37%, p=0.032) and at three months postoperatively (median: -3.58% vs. -6.12%, p=0.038).
CONCLUSION: There was a statistically significant difference in the rate of decrease in DI after gastrectomy between the C and NC groups at 1 and 3 months postoperatively. Our results suggest that patients with postoperative surgical complications require additional nutritional treatment for decreased DI.
Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. Patients will be off study at the time of death. All patients will be followed for survival every 6 months throughout their lifetime. Survival status may be obtained by phone call, clinical visit or medical records (e.g. physician notes/laboratory results of clinic or hospital visit.
Pediatric acute lymphoblastic leukemia (ALL) is marked by low mutational load at initial diagnosis, which increases at relapse. To determine which processes are active in (relapsed) ALL and how they behave during disease progression before and after therapy, we performed whole genome sequencing on 97 tumor samples of 29 multiply relapsed ALL patients. Mutational load increased upon relapse in 28 patients and upon every subsequent relapse in 22 patients. In addition to two clock-like mutational processes, we identified UV-like damage, APOBEC activity, reactive oxygen species, thiopurine-associated damage and an unknown therapy component as drivers of mutagenesis. Mutational processes often affected patients over longer time periods, but could also occur in isolated events, suggesting the requirement of additional triggers. Thiopurine exposure was the most prominent source of new mutations in relapse, affecting over half of the studied patients in first and/or later relapse and causing potential relapse-driving mutations in multiple patients. Our data demonstrate that multiple mutational processes frequently act in parallel as prominent secondary drivers with dynamic activity during ALL development and progression.
A dispatcher in a system for providing computer aided detection services for patient cases is disclosed. The dispatcher dynamically accepts cases from external devices and manages distribution of the cases among one or more image processing servers. The dispatcher includes a job dispatcher process, which creates a child dispatcher process for each connection to an external device in one-to-one correspondence, and a registration service for managing operating status information for one or more image processing servers. Each child process is assigned responsibility for managing an association for a connection. Establishing an association involves accepting or rejecting a case and dispatching the case to an image processing server. Each child dispatcher process is allocated its own dedicated cache memory for temporary storage of incoming image files. Thus, a dispatcher is disclosed that is capable of managing a large number of cases with high throughput in performing computer aided detection that is limited only by the amount of main memory in the computer running the dispatcher.